Modification of allergic bronchoconstriction by a calcium antagonist: Mode of action

E. W. Russi, B. Marchette, L. Yerger, W. M. Abraham, T. Ahmed

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Because both degranulation of mast cells and contraction of airway smooth muscle are dependent upon the influx of calcium, a calcium blocking agent might modify allergic bronchoconstriction by at least these two mechanisms. We treated sheep allergic to Ascaris suum antigen with the calcium antagonist Verapamil® prior to airway challenge with an aerosol of Ascaris suum antigen and also investigated the response without pretreatment. Aerosolized Ascaris suum antigen increased mean pulmonary resistance (RL) to 530% of baseline (n = 6). Pretreatment with intravenously administered Verapamil (150 μg/kg) increased mean RL to 225% of baseline but bronchoconstriction produced by subsequent antigen challenge was completely prevented. Verapamil did not modify bronchoconstriction produced by aerosols of histamine and carbachol, agents that act upon airway smooth muscle. Further, it did not reverse the increase in RL induced by an intravenous infusion of carbachol. These results suggest that verapamil, at the dosage used, did not prevent allergic bronchoconstriction by a direct action on smooth muscle and therefore was effective by inhibiting the release of mast cell mediators.

Original languageEnglish
Pages (from-to)675-679
Number of pages5
JournalAmerican Review of Respiratory Disease
Volume127
Issue number6
StatePublished - Jul 29 1983
Externally publishedYes

Fingerprint

Bronchoconstriction
Verapamil
Ascaris suum
Calcium
Smooth Muscle
Antigens
Carbachol
Aerosols
Mast Cells
Histamine Agents
Intravenous Infusions
Sheep
Lung

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Russi, E. W., Marchette, B., Yerger, L., Abraham, W. M., & Ahmed, T. (1983). Modification of allergic bronchoconstriction by a calcium antagonist: Mode of action. American Review of Respiratory Disease, 127(6), 675-679.

Modification of allergic bronchoconstriction by a calcium antagonist : Mode of action. / Russi, E. W.; Marchette, B.; Yerger, L.; Abraham, W. M.; Ahmed, T.

In: American Review of Respiratory Disease, Vol. 127, No. 6, 29.07.1983, p. 675-679.

Research output: Contribution to journalArticle

Russi, EW, Marchette, B, Yerger, L, Abraham, WM & Ahmed, T 1983, 'Modification of allergic bronchoconstriction by a calcium antagonist: Mode of action', American Review of Respiratory Disease, vol. 127, no. 6, pp. 675-679.
Russi EW, Marchette B, Yerger L, Abraham WM, Ahmed T. Modification of allergic bronchoconstriction by a calcium antagonist: Mode of action. American Review of Respiratory Disease. 1983 Jul 29;127(6):675-679.
Russi, E. W. ; Marchette, B. ; Yerger, L. ; Abraham, W. M. ; Ahmed, T. / Modification of allergic bronchoconstriction by a calcium antagonist : Mode of action. In: American Review of Respiratory Disease. 1983 ; Vol. 127, No. 6. pp. 675-679.
@article{962c9f4d91aa450883c700f41a0fa35d,
title = "Modification of allergic bronchoconstriction by a calcium antagonist: Mode of action",
abstract = "Because both degranulation of mast cells and contraction of airway smooth muscle are dependent upon the influx of calcium, a calcium blocking agent might modify allergic bronchoconstriction by at least these two mechanisms. We treated sheep allergic to Ascaris suum antigen with the calcium antagonist Verapamil{\circledR} prior to airway challenge with an aerosol of Ascaris suum antigen and also investigated the response without pretreatment. Aerosolized Ascaris suum antigen increased mean pulmonary resistance (RL) to 530{\%} of baseline (n = 6). Pretreatment with intravenously administered Verapamil (150 μg/kg) increased mean RL to 225{\%} of baseline but bronchoconstriction produced by subsequent antigen challenge was completely prevented. Verapamil did not modify bronchoconstriction produced by aerosols of histamine and carbachol, agents that act upon airway smooth muscle. Further, it did not reverse the increase in RL induced by an intravenous infusion of carbachol. These results suggest that verapamil, at the dosage used, did not prevent allergic bronchoconstriction by a direct action on smooth muscle and therefore was effective by inhibiting the release of mast cell mediators.",
author = "Russi, {E. W.} and B. Marchette and L. Yerger and Abraham, {W. M.} and T. Ahmed",
year = "1983",
month = "7",
day = "29",
language = "English",
volume = "127",
pages = "675--679",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Modification of allergic bronchoconstriction by a calcium antagonist

T2 - Mode of action

AU - Russi, E. W.

AU - Marchette, B.

AU - Yerger, L.

AU - Abraham, W. M.

AU - Ahmed, T.

PY - 1983/7/29

Y1 - 1983/7/29

N2 - Because both degranulation of mast cells and contraction of airway smooth muscle are dependent upon the influx of calcium, a calcium blocking agent might modify allergic bronchoconstriction by at least these two mechanisms. We treated sheep allergic to Ascaris suum antigen with the calcium antagonist Verapamil® prior to airway challenge with an aerosol of Ascaris suum antigen and also investigated the response without pretreatment. Aerosolized Ascaris suum antigen increased mean pulmonary resistance (RL) to 530% of baseline (n = 6). Pretreatment with intravenously administered Verapamil (150 μg/kg) increased mean RL to 225% of baseline but bronchoconstriction produced by subsequent antigen challenge was completely prevented. Verapamil did not modify bronchoconstriction produced by aerosols of histamine and carbachol, agents that act upon airway smooth muscle. Further, it did not reverse the increase in RL induced by an intravenous infusion of carbachol. These results suggest that verapamil, at the dosage used, did not prevent allergic bronchoconstriction by a direct action on smooth muscle and therefore was effective by inhibiting the release of mast cell mediators.

AB - Because both degranulation of mast cells and contraction of airway smooth muscle are dependent upon the influx of calcium, a calcium blocking agent might modify allergic bronchoconstriction by at least these two mechanisms. We treated sheep allergic to Ascaris suum antigen with the calcium antagonist Verapamil® prior to airway challenge with an aerosol of Ascaris suum antigen and also investigated the response without pretreatment. Aerosolized Ascaris suum antigen increased mean pulmonary resistance (RL) to 530% of baseline (n = 6). Pretreatment with intravenously administered Verapamil (150 μg/kg) increased mean RL to 225% of baseline but bronchoconstriction produced by subsequent antigen challenge was completely prevented. Verapamil did not modify bronchoconstriction produced by aerosols of histamine and carbachol, agents that act upon airway smooth muscle. Further, it did not reverse the increase in RL induced by an intravenous infusion of carbachol. These results suggest that verapamil, at the dosage used, did not prevent allergic bronchoconstriction by a direct action on smooth muscle and therefore was effective by inhibiting the release of mast cell mediators.

UR - http://www.scopus.com/inward/record.url?scp=0020530322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020530322&partnerID=8YFLogxK

M3 - Article

C2 - 6859650

AN - SCOPUS:0020530322

VL - 127

SP - 675

EP - 679

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -